Overview

A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This study was not conducted in the United States. The purpose of this study was to assess the safety and effectiveness of a number of doses of vildagliptin, an unapproved drug, in the treatment of people with type 2 diabetes.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Treatments:
Vildagliptin